Murat Bektas, Murat Selda, Ozgeyik Mehmet, Bilgin Muzaffer
Eskisehir City Hospital, Department of Cardiology, Eskisehir, Turkey.
Eskisehir Osmangazi University, Medical Faculty Department of Cardiology, Eskisehir, Turkey.
Eur J Clin Invest. 2023 Jan;53(1):e13872. doi: 10.1111/eci.13872. Epub 2022 Sep 20.
Atherosclerosis is a process that causes coronary artery disease and is associated with the inflammatory response. In this study, we aimed to evaluate the association of Pan-Immune-Inflammation Value (PIV) with in-hospital and long-term mortality in STEMI patients.
A total of 658 patients who were admitted to the emergency department of two tertiary centers with the diagnosis of STEMI and underwent percutaneous coronary intervention (PCI) between 2018 and 2022 were retrospectively enrolled. PIV and other inflammation parameters were compared for the study population. The primary outcome was one-year all-cause of mortality.
The mean age was 58.7 ± 17.1 years and 507 (76.9%) were male. The mean duration of the follow-up was 18.8 ± 8.5 months (median 18.9 months). PIV was superior to the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index for the prediction of primary and secondary outcomes in STEMI.
Our study reveals that PIV is a better predictor of mortality in STEMI patients. Prospective studies are needed to validate this biomarker.
动脉粥样硬化是一种导致冠状动脉疾病的过程，与炎症反应相关。在本研究中，我们旨在评估全免疫炎症值（PIV）与ST段抬高型心肌梗死（STEMI）患者住院期间及长期死亡率的相关性。
回顾性纳入2018年至2022年间在两家三级中心急诊科就诊并诊断为STEMI且接受经皮冠状动脉介入治疗（PCI）的658例患者。对研究人群的PIV和其他炎症参数进行比较。主要结局是一年全因死亡率。
平均年龄为58.7±17.1岁，男性507例（76.9%）。平均随访时间为18.8±8.5个月（中位数18.9个月）。在预测STEMI的主要和次要结局方面，PIV优于中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值和全身免疫炎症指数。
我们的研究表明，PIV是STEMI患者死亡率的更好预测指标。需要进行前瞻性研究来验证这一生物标志物。
